Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment

PURPOSE: U.S. Food and Drug Administration (FDA) recommended telavancin dosing is based on total body weight (TBW) but lacks adjusted regimens for obese subjects with varying renal function. Our aim was to develop a physiologically based pharmacokinetic (PBPK) model of telavancin to design optimized...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wanhong, Ke, Meng, Ye, Lingling, Lin, Cuihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808764/
https://www.ncbi.nlm.nih.gov/pubmed/33447912
http://dx.doi.org/10.1007/s00228-020-03072-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808764/
https://www.ncbi.nlm.nih.gov/pubmed/33447912
http://dx.doi.org/10.1007/s00228-020-03072-y

Ejemplares similares